2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rigatto, C. Articles by Jeffery, J. Search for Related Content PubMed PubMed Citation Articles by Rigatto, C. Articles by Jeffery, J.

Congestive Heart Failure in Renal Transplant Recipients: Risk Factors, Outcomes, and Relationship with Ischemic Heart Disease

Claudio Rigatto^*, Patrick Parfrey, Robert Foley, Carol Negrijn, Carrie Tribula^* and John Jeffery^*

*Section of Nephrology, University of Manitoba, Winnipeg, Canada; and Department of Medicine and Clinical Epidemiology Unit, Memorial University of Newfoundland, St. John’s, Canada.

Correspondence to: Dr. Claudio Rigatto, Assistant Professor of Medicine, University of Manitoba, Section of Nephrology, St. Boniface Hospital, 409 Tache Avenue, Winnipeg, Manitoba, Canada R2H 2A6. Phone: 204-237-2613; Fax: 204-233-2770; E-mail: crigatto{at}sbgh.mb.ca

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
ABSTRACT. Cardiovascular disease (CVD) is the major cause of death in renal transplant recipients (RTR). Several cohort studies have examined CVD in RTR, but none have addressed the development of congestive heart failure (CHF). CHF would hypothetically be a frequent and prognostically important event in RTR. A retrolective cohort study was, therefore, conducted in two Canadian centers to describe the incidence, risk factors for, and interrelationships between de novo CHF, de novo ischemic heart disease (IHD), and mortality in 638 consecutive adult RTR who were free of cardiac disease at 1 yr posttransplant. Detailed clinic and hospital records were available for 99% of patients. Median follow-up was 7 yr (range, 1 to 28 yr). De novo CHF occurred as frequently as de novo IHD (1.26 versus 1.22 events/100 patient-years, respectively) and appeared to carry a similar prognosis (relative risk for death, 1.78 [confidence interval, 1.21 to 2.61] for CHF versus 1.50 [1.05 to 2.13] for IHD). The incidence of CHF was considerably higher than that in the Framingham cohort, whereas the incidence of IHD was not, suggesting that renal transplantation might correspond more to a state of "accelerated heart failure" than to "accelerated atherosclerosis." Age, diabetes, gender, BP, and anemia were identified as independent risk factors for de novo CHF, whereas age, diabetes, gender, BP, and rejection were independent risk factors for de novo IHD. Optimal strategies for treatment of BP and anemia in RTR will need to be determined in randomized controlled trials.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cardiovascular disease (CVD) is the major cause of death among renal transplant recipients (RTR) (1,2). The manifestations of cardiac disease comprise both disorders of perfusion, presenting primarily as ischemic heart disease (IHD; e.g., myocardial infarction [MI], angina pectoris) and disorders of left ventricular function, presenting primarily as congestive heart failure (CHF). Both CHF and IHD are important adverse prognostic markers in the general population. In dialysis patients, CHF occurs frequently and is a stronger predictor of mortality than IHD (3).

Although several high-quality cohort studies have addressed the subject of cardiovascular disease in RTR, none have examined the incidence, determinants, and prognosis of CHF in renal transplants (1,2,4–7). As renal transplantation is often a state of chronic renal insufficiency, we hypothesized that CHF would occur frequently, would be associated with potentially reversible risk factors, and would be a prognostically important event among RTR. We therefore conducted a retrolective cohort study in two Canadian centers to describe the risk factors for and interrelationships between de novo CHF, de novo IHD, and mortality in a cohort of patients who were alive with a functioning graft and free of clinical cardiac disease at 1 yr after transplantation.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Design
Cohort Definition.
We assembled a retrolective cohort of 638 consecutive adult RTR (age, >18 yr) who were followed since inception in Winnipeg, Manitoba (n = 473) and St. John’s, Newfoundland (n = 165). Patients were included in the cohort if they were alive with functioning graft and free of clinical heart disease at 1 yr after transplantation. Patients with known pretransplant cardiac disease were excluded, because cardiac disease at the time of transplantation is due to risk exposures before transplantation and might confound the relationship between posttransplant risk factors and subsequent outcomes. Patients having events in the first year were excluded because events in the first year could not be reasonably attributed to posttransplant variables measured during the same interval. The cohort as defined comprised 62% of all consecutive RTR followed in Manitoba and Newfoundland between 1969 and 1999.

The Manitoba patients received transplants between 1969 and 1999, and the Newfoundland patients received transplants between 1975 and 1999. All patients were followed exclusively at the Health Sciences Center, Winnipeg, and the Health Sciences Center, St. John’s. Detailed clinic and hospital records were available for 99% of patients. Trained research nurses reviewed all inpatient and outpatient records, abstracting data on baseline demographic, clinical, and outcome variables. The detail available permitted systematic application of a priori definitions for most outcomes.

Study Variables and Definitions.
Baseline Variables.
Age, gender, presence or absence of diabetes, living or cadaveric donor status, and smoking status were abstracted from the pretransplant assessment records. IHD and CHF were judged to be absent at baseline if the pretransplant assessment concluded that they were absent. Cardiovascular disease was a focus of the pretransplant assessment protocol, and diagnosis was based on oral history, records review, physical examination, and electrocardiogram, with further testing reserved for symptomatic individuals or diabetics. Hypertension before transplantation was defined as BP >140/90 mmHg or need for antihypertensive therapy. Use of angiotensin-converting enzyme inhibitors was recorded. Era of transplantation was defined as transplantation before or after 1985, the year in which cyclosporine became part of the routine maintenance immunosuppression protocol at both centers. Before 1985, the majority of patients received azathioprine and prednisone alone. Delayed graft function was defined as need for dialysis in the first 2 wk after renal transplantation. Acute rejection was defined as an acute rise in serum creatinine of at least 10% that was not attributable to prerenal causes, obstruction, or cyclosporine toxicity and that was treated with pulse steroids and/or antilymphocyte preparations. Delayed graft function (DGF) was defined as need for dialysis in the first 2 wk after transplantation. Systolic and diastolic BP, hemoglobin, albumin, and serum creatinine were measured at least quarterly per clinic protocol, and total cholesterol was measured yearly.

Outcome Variables.
CHF was defined clinically as dyspnea plus two of the following: raised jugular venous pressure, bibasilar crackles, chest x-ray evidence of pulmonary venous hypertension, or pulmonary edema (8). De novo CHF was defined as CHF occurring for the first time in a patient previously free of CHF. An episode of IHD was defined as hospitalization for acute MI or revascularization (coronary artery bypass grafting or percutaneous transluminal angioplasty). MI was defined as the presence of chest pain accompanied by characteristic electrocardiogram changes of infarction or a threefold elevation in creatine kinase levels. Cardiovascular death was defined as death from myocardial infarction or a revascularization procedure, cardiogenic shock, primary arrhythmia, stroke, or ruptured aortic aneurysm.

Statistical Analyses
Normally distributed continuous variables are expressed as mean (SD); non-normally distributed variables are expressed as median (interquartile range). Categorical variables are expressed as percentages. Outcomes are described using event-free Kaplan-Meier survival curves. Patients were censored at graft failure, latest follow-up, or death, except where death was the end point being analyzed. Cox proportional hazards regression was used for both univariate and multivariate analyses. Backwards conditional stepping operative on the complete variable pool was used to select the best multivariate model. The proportional hazards assumption was checked by inspection of the log (-log)-transformed survival curves. Values for systolic BP, diastolic BP, hemoglobin, creatinine, Gault-Cockroft creatinine clearance, and albumin were averaged over the first year for each patient. If more than one total cholesterol level was available in the first year, these were also averaged.

Time-Dependent Analyses.
To estimate the impact of intermediate events (i.e., de novo CHF and IHD) occurring at variable follow-up times on subsequent mortality, time-dependent variables were created and included in a time-dependent proportional hazards analysis (9). For the case of CHF, the time-dependent variable created was assigned a value of 0 for follow-up times before the first de novo CHF episode and a value of 1 for follow-up times after the first episode. For patients who did not develop de novo CHF, the time-dependent variable was always 0. The time-dependence of de novo IHD was handled in the same way. The independent effect of de novo IHD and CHF on mortality was estimated by including both time-dependent covariates in the same model. CHF and IHD were assessed independently, and the observations were not mutually exclusive; therefore, the model correctly handled the occurrence of both events in the same patient. The impact of de novo IHD on subsequent CHF was handled analogously by including the time-dependent IHD variable as a covariate in a proportional hazards model of predictors of de novo CHF. Only IHD events preceding or coincident with CHF were analyzed this way, because events occurring after the development of CHF cannot be causally associated with that end point.

Missing Values.
Missing values were replaced by random imputation (10). The proportion of values randomly imputed were as follows: creatinine clearance, 4%; hemoglobin, 7.7%; BP, 7.8%; albumin, 12.5%; cholesterol, 41%; smoking, 15.7%; and DGF, 26%. All other variables were complete. The random imputation procedure was repeated four times, and the data were reanalyzed using each set of imputed values to test the robustness of the results. As an additional check, multivariate normal imputation was used (11). The resultant models were nearly identical; therefore, the imputation method had negligible impact on the results.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Patient Characteristics
Of the 1021 adult patients followed since inception at both centers from 1969 to 1999, 638 (62%) were alive with functioning graft and free of cardiac disease at 1 yr (Figure 1). Selected baseline characteristics and averaged clinical and laboratory variables in the first year are summarized in Table 1.

View larger version (24K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 1. Source of the cohort analyzed for de novo heart disease.

View larger version (8K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 2. Kaplan-Meier event-free survival curves for de novo congestive heart failure (CHF) (A) and de novo ischemic heart disease (IHD) (B).

View larger version (21K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 3. Relative hazard (risk) of de novo CHF as a function of hemoglobin quartile in a cohort of 638 renal transplant recipients (RTR) alive with functioning graft and free of clinical heart disease at 1 yr posttransplant. **Adjusted for age, diabetes, systolic BP, donor status, and serum albumin; P < 0.03 with respect to reference quartile.

View larger version (15K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 4. Relative hazard (risk) of de novo CHF as a function of systolic and diastolic BP quartiles in a cohort of 638 RTR alive with functioning graft and free of clinical heart disease at 1 yr posttransplant.

Incidence and Determinants of De Novo IHD
Sixty-one patients developed de novo IHD over the observation period. The average incidence was 1.22 events/100 patient-years, the same as that of de novo CHF. The cumulative incidence of de novo IHD, estimated using the Kaplan-Meier method, was 4.5% (2.7 to 6.3%) at 5 yr, 11.5% (8.1 to 14.9%) at 10 yr, and 22.9% (15.5 to 30.3%) at 20 yr (Figure 2B). On univariate analysis (Table 3), age, gender, diabetes, BP, and allograft rejection were significant predictors of de novo IHD, and these associations persisted in the multivariate analysis (Table 3). A center effect was observed in the univariate analysis but disappeared in the multivariate model, suggesting the effect was due to case-mix differences between centers.

View larger version (12K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 5. Survival in patients who did and did not develop de novo CHF (A) and de novo IHD (B).

Determinants of Mortality
Overall mortality in this healthy cohort was low (2.5 deaths/100 patient-years). Nearly half the deaths were from cardiovascular causes (Table 5). As expected, factors predicting de novo CHF or IHD (i.e., age, diabetes, anemia, hypertension, cadaveric donation, and smoking) also predicted all-cause and cardiovascular death (Table 6).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

Our multivariate analysis showed that age, diabetes, development of IHD, BP, anemia, serum albumin, and cadaveric donation were independently associated with de novo CHF. Although IHD appears to be an important element in the causation of CHF, de novo IHD preceded de novo CHF in only 18 (29%) of 63 patients, suggesting other factors are responsible in many cases. Hypertension and anemia are recognized hemodynamic stressors and imparted substantial risk of CHF even after adjustment for de novo IHD. Several direct and indirect observations support a causal association between these hemodynamic factors and CHF. First, both anemia and hypertension were documented to exist well before the development of CHF. Second, a monotonic increasing risk of CHF was observed with worsening hypertension and anemia (Figures 3 and 4), consistent with a causal association. Third, studies in renal transplantation, chronic renal insufficiency, and dialysis have consistently documented the association between hypertension/anemia and left ventricular growth (15–17). It is therefore plausible that anemia and hypertension promoted ventricular growth and remodeling in our cohort, leading to congestive heart failure.

The role of hypoalbuminemia in the development of CHF is less clear. Hypoalbuminemia has also been associated with congestive heart failure and progressive left ventricular cavity enlargement in dialysis patients (18). It is thought to be a marker of malnutrition and/or chronic inflammation, either of which could promote cardiomyocyte attrition, cardiomyopathy, and CHF (19). The role of cadaveric donation in the genesis of CHF is probably noncausal, reflecting unmeasured patient selection biases, with cadaveric kidneys being preferred in cases of marginal recipients.

Although acute rejection was not directly associated with de novo CHF, it was predictive of de novo IHD, which in turn predicted de novo CHF. Acute rejection was not a marker for the adverse risk associated with steroid or OKT3 treatment, because neither factor was linked to cardiac outcomes (data not shown). Repeated episodes of acute rejection may cause upregulation of acute phase reactants, such as CRP. These factors have been independently associated with adverse cardiac events in the general population (20). A similar association may pertain in RTR.

Renal function was not an independent predictor of incident IHD or CHF. Multivariate modeling suggested that the impact of renal function on CHF is largely the result of hypertension and anemia, known correlates of renal failure. Similarly, immunosuppressive regimen was not associated with cardiovascular outcomes after multivariate adjustment.

These observations may be integrated into the pathophysiologic schema proposed in Figure 6. In this hypothesis, age, diabetes, and markers of unmeasured patient factors (e.g., cadaveric donation) determine the baseline cardiac geometry. Chronic hemodynamic stresses from anemia and hypertension promote wall hypertrophy and cavity enlargement. Tissue ischemia (i.e., IHD), malnutrition, and inflammation contribute to cardiomyocyte death and left ventricular dilation. The resultant cardiomyopathy is clinically expressed as CHF. Although omitted for clarity, factors such as renal function, rejection, and immunosuppressive medications can still influence development of CHF indirectly via effects on BP, anemia, nutrition, and IHD. Further testing of this framework will require clinical trials of risk factor interventions, especially for hypertension and anemia, here identified as major reversible risk factors.

View larger version (14K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 6. Pathogenesis of CHF in RTR: A hypothesis.

In conclusion, de novo CHF occurs as commonly as de novo IHD in RTR, and it carries a similar adverse prognosis. The incidence of CHF appears to be considerably higher than that in the general population, whereas the incidence of IHD was not, suggesting that renal transplantation may correspond better to a state of "accelerated heart failure" than to one of "accelerated atherosclerosis." Age, diabetes, gender, BP, and anemia appear to be dominant risk factors in the development of de novo CHF, whereas age, diabetes, gender, BP, and rejection appear to be dominant risk factors for de novo IHD in renal transplant recipients. Effective strategies for treatment of reversible risk factors, in particular BP and anemia, will need to be determined in randomized controlled trials.

	Acknowledgments

 
This study was supported by an unrestricted educational grant from Janssen-Ortho Canada. Dr. Rigatto is a recipient of the Kidney Foundation of Canada Biomedical Fellowship 1998–2000. Dr. Parfey holds a Distinguished Scientist Award from the Canadian Institute for Health Research.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Kasiske BL: Risk factors for accelerated atherosclerosis in renal transplant patients. Am J Med 84: 985–992, 1988[CrossRef][Medline]
2. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G: Ischemic Heart Disease- major cause of death and graft loss after transplantation in Scandinavia. Transplantation 60: 451–457, 1995[Medline]
3. Foley R, Parfrey P, Harnett J, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in end-stage renal disease: prevalence, associations, and risk factors. Kidney Int 47: 186–192, 1995[Medline]
4. Kasiske B, Guijarro C, Massy Z, Wiederkehr MR, Ma JZ.: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7: 158–165, 1996[Abstract]
5. Kasiske B, Harini C, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11: 1735–1743, 2000[Abstract/Free Full Text]
6. Aker S, Ivens K, Grabensee B, Heering P: Cardiovascular complications after renal transplantation. Transplant Proc 30: 2039–2042, 1998[CrossRef][Medline]
7. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM: Serum total homocysteine and cardiovascular disease occurrence in chronic stable transplant recipients: A prospective study. J Am Soc Nephrol 11: 134–137, 2000[Abstract/Free Full Text]
8. Harnett J, Foley R, Kent G, Barre P, Murray D, Parfrey P: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 47: 884–890, 1995[Medline]
9. Cox D, Oakes D: Analysis of Survival Data, New York, Chapman and Hall, 1983
10. Rubin D, Schenker N: Multiple imputation in health care databases: An overview and some applications. Stat Med 10: 585–598, 1991[Medline]
11. Lipsitz S, Molenberghs G, Fitzmaurice G, Ibrahim J: GEE with Gaussian estimation of the correlations when data are incomplete. Biometrics 56: 528–536, 2000[CrossRef][Medline]
12. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE: Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 49: 1428–1434, 1996[Medline]
13. Senni M, Tribouilly C, Rodeheffer R, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM: Congestive heart failure in the community: trends in incidence and survival in a 10 year period. Arch Intern Med 159: 29–34, 1999[Abstract/Free Full Text]
14. Ho K, Pinsky J, Kannel W, Levy D: The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 22: 6A–13A, 1993
15. Culleton BF, Larson MG, Wilson PWF, Evan JC, Parfrey PS, Levy D: Cardiovascular disease and mortality in a community based cohort with mild renal insufficiency. Kidney Int 56: 2214–2219, 1999[CrossRef][Medline]
16. Peteiro J, Alvarez N, Calvino R, Penas M, Ribera F, Castro Beiras A: Changes in left ventricular mass and filling after renal transplantation are related to changes in blood pressure: An echocardiographic and pulsed Doppler study. Cardiology 85: 273–283, 1994[CrossRef][Medline]
17. Rigatto C, Foley RN, Kent GM, Guttmann R, Parfrey PS: Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation 70: 570–575, 2000[CrossRef][Medline]
18. Levin A, Thompson CR, Ethier J: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34: 125–134, 1999[Medline]
19. Rigatto C, Parfrey P, London G: Cardiac hypertrophy in end-stage renal failure.In: Cardiovascular Disease in End-Stage Renal Failure,edited by Loscalzo J, London G, Oxford, Oxford University Press, 2000,pp 157–175
20. Ridker P, Nader R, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AMJr: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344: 1959–65, 2001[Abstract/Free Full Text]

This article has been cited by other articles:

				D. Chhabra, M. Grafals, A. I. Skaro, M. Parker, and L. Gallon Impact of Anemia after Renal Transplantation on Patient and Graft Survival and on Rate of Acute Rejection Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1168 - 1174. [Abstract] [Full Text] [PDF]

				A. M. de Mattos, A. Siedlecki, R. S. Gaston, G. J. Perry, B. A. Julian, C. E. Kew II, M. H. Deierhoi, C. Young, J. J. Curtis, and A. E. Iskandrian Systolic Dysfunction Portends Increased Mortality among Those Waiting for Renal Transplant J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1191 - 1196. [Full Text] [PDF]

				R. Borrows, M. Loucaidou, G. Chusney, S. Borrows, J. V. Tromp, T. Cairns, M. Griffith, N. Hakim, A. McLean, A. Palmer, et al. Anaemia and congestive heart failure early post-renal transplantation Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1728 - 1734. [Abstract] [Full Text] [PDF]

				B. Kiberd and R. Panek Cardiovascular Outcomes in the Outpatient Kidney Transplant Clinic: The Framingham Risk Score Revisited Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 822 - 828. [Abstract] [Full Text] [PDF]

				S. Aull-Watschinger, H. Konstantin, D. Demetriou, M. Schillinger, A. Habicht, W. H. Horl, and B. Watschinger Pre-transplant predictors of cerebrovascular events after kidney transplantation Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1429 - 1435. [Abstract] [Full Text] [PDF]

				J. S. Gill Cardiovascular Disease in Transplant Recipients: Current and Future Treatment Strategies Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S29 - S37. [Abstract] [Full Text] [PDF]

				W. C. Winkelmayer and A. Chandraker Pottransplantation Anemia: Management and Rationale Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S49 - S55. [Abstract] [Full Text] [PDF]

				K. T. Sinnamon, A. E. Courtney, A. P. Maxwell, P. T. McNamee, G. Savage, and D. G. Fogarty Level of renal function and serum erythropoietin levels independently predict anaemia post-renal transplantation Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1969 - 1973. [Abstract] [Full Text] [PDF]

				W. H. Horl, Y. Vanrenterghem, P. Aljama, P. Brunet, R. Brunkhorst, L. Gesualdo, I. Macdougall, C. Wanner, and B. Wikstrom OPTA: Optimal treatment of anaemia in patients with chronic kidney disease (CKD) Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_3): iii20 - iii26. [Full Text] [PDF]

				F. Moreso and J. M. Grinyo Graft dysfunction and cardiovascular risk--an unholy alliance Nephrol. Dial. Transplant., March 1, 2007; 22(3): 699 - 702. [Full Text] [PDF]

				S. D. Roger and A. Levin Epoetin trials: randomised controlled trials don't always mimic observational data Nephrol. Dial. Transplant., March 1, 2007; 22(3): 684 - 686. [Full Text] [PDF]

				W. C. Winkelmayer, A. Chandraker, M. Alan Brookhart, R. Kramar, and G. Sunder-Plassmann A prospective study of anaemia and long-term outcomes in kidney transplant recipients Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3559 - 3566. [Abstract] [Full Text] [PDF]

				R. Marcen, J. M. Morales, M. Arias, G. Fernandez-Juarez, G. Fernandez-Fresnedo, A. Andres, E. Rodrigo, J. Pascual, B. Dominguez, and J. Ortuno Ischemic Heart Disease after Renal Transplantation in Patients on Cyclosporine in Spain J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S286 - S290. [Abstract] [Full Text] [PDF]

				A. E. Imoagene-Oyedeji, S. E. Rosas, A. M. Doyle, S. Goral, and R. D. Bloom Posttransplantation Anemia at 12 Months in Kidney Recipients Treated with Mycophenolate Mofetil: Risk Factors and Implications for Mortality J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3240 - 3247. [Abstract] [Full Text] [PDF]

				A. Djamali, M. Samaniego, B. Muth, R. Muehrer, R. M. Hofmann, J. Pirsch, A. Howard, G. Mourad, and B. N. Becker Medical Care of Kidney Transplant Recipients after the First Posttransplant Year Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 623 - 640. [Abstract] [Full Text] [PDF]

				H. Bozbas, A. Yildirir, and H. Muderrisoglu Cardiac enzymes, renal failure and renal transplantation. Clin. Med. Res., March 1, 2006; 4(1): 79 - 84. [Abstract] [Full Text] [PDF]

				D. J. Kennedy, S. Vetteth, S. M. Periyasamy, M. Kanj, L. Fedorova, S. Khouri, M. B. Kahaleh, Z. Xie, D. Malhotra, N. I. Kolodkin, et al. Central Role for the Cardiotonic Steroid Marinobufagenin in the Pathogenesis of Experimental Uremic Cardiomyopathy Hypertension, March 1, 2006; 47(3): 488 - 495. [Abstract] [Full Text] [PDF]

				C. D. Hanevold, P.-L. Ho, L. Talley, and M. M. Mitsnefes Obesity and Renal Transplant Outcome: A Report of the North American Pediatric Renal Transplant Cooperative Study Pediatrics, February 1, 2005; 115(2): 352 - 356. [Abstract] [Full Text] [PDF]

				K. C. Abbott, F. C. Trespalacios, L. Y. Agodoa, A. J. Taylor, and G. L. Bakris {beta}-Blocker Use in Long-term Dialysis Patients: Association With Hospitalized Heart Failure and Mortality Arch Intern Med, December 13, 2004; 164(22): 2465 - 2471. [Abstract] [Full Text] [PDF]

				C. C. Magee and M. Pascual Update in Renal Transplantation Arch Intern Med, July 12, 2004; 164(13): 1373 - 1388. [Abstract] [Full Text] [PDF]

				L. P. McMahon, S. D. Roger, and A. Levin Development, Prevention, and Potential Reversal of Left Ventricular Hypertrophy in Chronic Kidney Disease J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1640 - 1647. [Abstract] [Full Text] [PDF]

				M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension, November 1, 2003; 42(5): 1050 - 1065. [Full Text] [PDF]

				M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation, October 28, 2003; 108(17): 2154 - 2169. [Full Text] [PDF]

				K. C. Abbott, C. M. Yuan, A. J. Taylor, D. F. Cruess, and L. Y. C. Agodoa Early Renal Insufficiency and Hospitalized Heart Disease after Renal Transplantation in the Era of Modern Immunosuppression J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2358 - 2365. [Abstract] [Full Text] [PDF]

				D. Mozaffarian, R. Nye, and W. C. Levy Anemia predicts mortality in severe heart failure: The prospective randomized amlodipine survival evaluation (PRAISE) J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1933 - 1939. [Abstract] [Full Text] [PDF]

				D. Silverberg Outcomes of anaemia management in renal insufficiency and cardiac disease Nephrol. Dial. Transplant., June 1, 2003; 18(suppl_2): ii7 - ii12. [Abstract] [Full Text] [PDF]

				C. Rigatto, R. Foley, J. Jeffery, C. Negrijn, C. Tribula, and P. Parfrey Electrocardiographic Left Ventricular Hypertrophy in Renal Transplant Recipients: Prognostic Value and Impact of Blood Pressure and Anemia J. Am. Soc. Nephrol., February 1, 2003; 14(2): 462 - 468. [Abstract] [Full Text] [PDF]

				K. C. Abbott, J. R. Bucci, D. Cruess, A. J. Taylor, and L. Y.C. Agodoa Graft Loss and Acute Coronary Syndromes after Renal Transplantation in the United States J. Am. Soc. Nephrol., October 1, 2002; 13(10): 2560 - 2569. [Abstract] [Full Text] [PDF]

				C. Rigatto, P. Parfrey, V. M. Montori, A. Basu, Y. C. Kudva, C. L. Baum, A. P. McGee, A. Friedman, A. Friedman, M. Pascual, et al. Strategies to Improve Outcomes after Renal Transplantation N. Engl. J. Med., June 27, 2002; 346(26): 2089 - 2092. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal